Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715, ALLO-605, ALLO-316, and ALLO-647.
Number of employees : 265 people.
|Pfizer Inc. ||27,349,211||
|TPG Group Holdings (SBS) Advisors, Inc. ||18,716,306||
|Gilead Sciences, Inc. ||7,486,689||
|Seaview Trust ||7,340,867||
|The Vanguard Group, Inc. ||6,539,163||
|Capital Research & Management Co. (Global Investors) ||5,404,294||
|David Chang ||5,382,908||
|T. Rowe Price Associates, Inc. (Investment Management) ||4,338,991||
|Arie Belldegrun ||4,206,540||
|PRIMECAP Management Co. ||3,604,300||
|Company contact information|
Allogene Therapeutics, Inc.
210 East Grand Avenue
South San Francisco, CA 94080
Phone : +1.650.457.2700
Web : http://www.allogene.com
Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
Sector Bio Therapeutic Drugs
Connections : Allogene Therapeutics, Inc.